Trine Strandgaard
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Trine Strandgaard has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Iver Nordentoft
Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark
24 shared publications - Lars Dyrskjøt
Department of Clinical Medicine, Health, Aarhus University, Aarhus, Denmark
24 shared publications - Jørgen Bjerggaard Jensen
Department of Clinical Medicine Aarhus University Aarhus Denmark
23 shared publications - Karin Birkenkamp-Demtröder
Department of Molecular Medicine, Aarhus University Hospital
23 shared publications - Philippe Lamy
Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark
23 shared publications - Sia Viborg Lindskrog
Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark
23 shared publications
Latest Publications
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S13 from Cell-Free Urine and Plasma DNA Mutational Analysis Predicts Neoadjuvant Chemotherapy Response and Outcome in Patients with Muscle-Invasive Bladder Cancer
Supplementary Fig. 1. Overview of sample availability and in-silico analysis of the limit of detection for the applied methodology.Supplementary Fig. 2. Comparison between mutations observed in primary and residual tumors at radical cystectomy (RC).Supplementary Fig. 3. Mean sample VAF levels for plasma, urine pellet and urine supernatant split by tdDNA call status in other paired sample types from the same clinical visit.Supplementary Fig. 4. Association between mean sample VAF.Supplementary Fig. 5. Association between mean VAFSupplementary Fig. 6. Urine dipstick measurements compared to the amount of DNA extracted from urine supernatants collected at the same time (+/- 1 day).Supplementary Fig. 7. Urine dipstick measurements compared to the urinary tumor DNA (utDNA) call status in urine supernatants collected at the same time (+/- 1 day).Supplementary Fig. 8. Urine dipstick measurements compared to the urinary tumor DNA (utDNA) level in urine supernatants collected at the same time (+/- 1 day).Supplementary Fig. 9. Mean sample VAF levels for all patients with detectable tumor DNA split by sample type. Tumor stage evaluation was based on the TURB specimen and tumor DNA level based on samples collected before TURB.Supplementary Fig. 10. Kaplan-Meier survival analysis of recurrence-free survival (RFS) stratified by tumor DNA status for all sample types.Supplementary Fig. 11. Tumor DNA levels compared to NAC response.Supplementary Fig. 12. Kaplan-Meier survival analysis of recurrence-free survival (RFS) stratified by tumor DNA level for all sample types.Supplementary Fig. 13. a-b) Association between tumor DNA dynamics and neoadjuvant chemotherapy (NAC) response for a) urine pellet and b) urine supernatant. Tumor DNA clearance was defined as tumor DNA going from detectable to non-detectable and tumor DNA remains was defined as tumor DNA remaining detectable. c-d) Kaplan-Meier survival analysis of tumor DNA dynamics groups and recurrence-free survival (RFS) for c) urine pellet and d) urine supernatant.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S13 from Cell-Free Urine and Plasma DNA Mutational Analysis Predicts Neoadjuvant Chemotherapy Response and Outcome in Patients with Muscle-Invasive Bladder Cancer
Supplementary Fig. 1. Overview of sample availability and in-silico analysis of the limit of detection for the applied methodology.Supplementary Fig. 2. Comparison between mutations observed in primary and residual tumors at radical cystectomy (RC).Supplementary Fig. 3. Mean sample VAF levels for plasma, urine pellet and urine supernatant split by tdDNA call status in other paired sample types from the same clinical visit.Supplementary Fig. 4. Association between mean sample VAF.Supplementary Fig. 5. Association between mean VAFSupplementary Fig. 6. Urine dipstick measurements compared to the amount of DNA extracted from urine supernatants collected at the same time (+/- 1 day).Supplementary Fig. 7. Urine dipstick measurements compared to the urinary tumor DNA (utDNA) call status in urine supernatants collected at the same time (+/- 1 day).Supplementary Fig. 8. Urine dipstick measurements compared to the urinary tumor DNA (utDNA) level in urine supernatants collected at the same time (+/- 1 day).Supplementary Fig. 9. Mean sample VAF levels for all patients with detectable tumor DNA split by sample type. Tumor stage evaluation was based on the TURB specimen and tumor DNA level based on samples collected before TURB.Supplementary Fig. 10. Kaplan-Meier survival analysis of recurrence-free survival (RFS) stratified by tumor DNA status for all sample types.Supplementary Fig. 11. Tumor DNA levels compared to NAC response.Supplementary Fig. 12. Kaplan-Meier survival analysis of recurrence-free survival (RFS) stratified by tumor DNA level for all sample types.Supplementary Fig. 13. a-b) Association between tumor DNA dynamics and neoadjuvant chemotherapy (NAC) response for a) urine pellet and b) urine supernatant. Tumor DNA clearance was defined as tumor DNA going from detectable to non-detectable and tumor DNA remains was defined as tumor DNA remaining detectable. c-d) Kaplan-Meier survival analysis of tumor DNA dynamics groups and recurrence-free survival (RFS) for c) urine pellet and d) urine supernatant.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Cell-Free Urine and Plasma DNA Mutational Analysis Predicts Neoadjuvant Chemotherapy Response and Outcome in Patients with Muscle-Invasive Bladder Cancer
Summarized metrics for WES data
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Cell-Free Urine and Plasma DNA Mutational Analysis Predicts Neoadjuvant Chemotherapy Response and Outcome in Patients with Muscle-Invasive Bladder Cancer
Summarized metrics for WES data
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Cell-Free Urine and Plasma DNA Mutational Analysis Predicts Neoadjuvant Chemotherapy Response and Outcome in Patients with Muscle-Invasive Bladder Cancer
Clinical data and follow-up data
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Cell-Free Urine and Plasma DNA Mutational Analysis Predicts Neoadjuvant Chemotherapy Response and Outcome in Patients with Muscle-Invasive Bladder Cancer
Clinical data and follow-up data
- Open Access
Low T cell diversity is associated with poor outcome in bladder cancer: a comprehensive longitudinal analysis of the T cell receptor repertoire
Summary: T cells are one of the primary effector cells in the endogenous defense against cancer, yet the clinical impact of their quantity, diversity, and dynamics remains underexplored. Here we investigated the clinical relevance of the T cell receptor (TCR) repertoire in patients with bladder cancer. In advanced-stage bladder cancer, low pre-treatment peripheral TCR diversity was associated with worse overall survival (p=0.024), particularly when it coincided with a low fraction of circulating T cells (p=0.00049). The low-diversity TCR repertoires were dominated by expanded clones that persisted throughout treatment and disproportionately targeted latent viral infections. Longitudinal analysis revealed a reduction in TCR diversity after treatment indicating an adverse effect on the immune system. In early-stage bladder cancer, we showed that immunotherapy had a stimulatory effect on TCR diversity in patients with good outcomes. Single-cell sequencing identified most expanded clones as cytotoxic T cells, while non-expanded clones were predominantly naive T cells. Overall, our findings suggest that TCR diversity is a promising new biomarker that may offer new avenues for tailored oncological treatment to enhance clinical outcomes for bladder cancer patients.
Open AccessLow T cell diversity is associated with poor outcome in bladder cancer: a comprehensive longitudinal analysis of the T cell receptor repertoire
Summary: T cells are one of the primary effector cells in the endogenous defense against cancer, yet the clinical impact of their quantity, diversity, and dynamics remains underexplored. Here we investigated the clinical relevance of the T cell receptor (TCR) repertoire in patients with bladder cancer. In advanced-stage bladder cancer, low pre-treatment peripheral TCR diversity was associated with worse overall survival (p=0.024), particularly when it coincided with a low fraction of circulating T cells (p=0.00049). The low-diversity TCR repertoires were dominated by expanded clones that persisted throughout treatment and disproportionately targeted latent viral infections. Longitudinal analysis revealed a reduction in TCR diversity after treatment indicating an adverse effect on the immune system. In early-stage bladder cancer, we showed that immunotherapy had a stimulatory effect on TCR diversity in patients with good outcomes. Single-cell sequencing identified most expanded clones as cytotoxic T cells, while non-expanded clones were predominantly naive T cells. Overall, our findings suggest that TCR diversity is a promising new biomarker that may offer new avenues for tailored oncological treatment to enhance clinical outcomes for bladder cancer patients.
- Open Access
- 14 April 2023
- Published by American Association for Cancer Research (AACR)
Data from Cell-Free Urine and Plasma DNA Mutational Analysis Predicts Neoadjuvant Chemotherapy Response and Outcome in Patients with Muscle-Invasive Bladder Cancer
Purpose:To investigate the use of plasma and urine DNA mutation analysis for predicting neoadjuvant chemotherapy (NAC) response and oncological outcome in patients with muscle-invasive bladder cancer.Experimental Design:Whole-exome sequencing of tumor and germline DNA was performed for 92 patients treated with NAC followed by radical cystectomy (RC). A custom NGS-panel capturing approximately 50 mutations per patient was designed and used to track mutated tumor DNA in plasma and urine. A total of 447 plasma samples, 281 urine supernatants, and 123 urine pellets collected before, during, and after treatment were analyzed. Patients were enrolled from 2013 to 2019, with a median follow-up time of 41.3 months after RC.Results:We identified tumor DNA before NAC in 89% of urine supernatants, 85% of urine pellets, and 43% of plasma samples. Tumor DNA levels were higher in urine supernatants and urine pellets compared with plasma samples (P < 0.001). In plasma, detection of circulating tumor DNA (ctDNA) before NAC was associated with a lower NAC response rate (P < 0.001). Detection of tumor DNA after NAC was associated with lower response rates in plasma, urine supernatant, and urine pellet (P < 0.001, P = 0.03, P = 0.002). Tumor DNA dynamics during NAC was predictive of NAC response and outcome in urine supernatant and plasma (P = 0.006 and P = 0.002). A combined measure from plasma and urine supernatant tumor DNA dynamics stratified patients by outcome (P = 0.003).Conclusions:Analysis of tumor DNA in plasma and urine samples both separately and combined has a potential to predict treatment response and outcome.
- 14 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Cell-Free Urine and Plasma DNA Mutational Analysis Predicts Neoadjuvant Chemotherapy Response and Outcome in Patients with Muscle-Invasive Bladder Cancer
Purpose:To investigate the use of plasma and urine DNA mutation analysis for predicting neoadjuvant chemotherapy (NAC) response and oncological outcome in patients with muscle-invasive bladder cancer.Experimental Design:Whole-exome sequencing of tumor and germline DNA was performed for 92 patients treated with NAC followed by radical cystectomy (RC). A custom NGS-panel capturing approximately 50 mutations per patient was designed and used to track mutated tumor DNA in plasma and urine. A total of 447 plasma samples, 281 urine supernatants, and 123 urine pellets collected before, during, and after treatment were analyzed. Patients were enrolled from 2013 to 2019, with a median follow-up time of 41.3 months after RC.Results:We identified tumor DNA before NAC in 89% of urine supernatants, 85% of urine pellets, and 43% of plasma samples. Tumor DNA levels were higher in urine supernatants and urine pellets compared with plasma samples (P < 0.001). In plasma, detection of circulating tumor DNA (ctDNA) before NAC was associated with a lower NAC response rate (P < 0.001). Detection of tumor DNA after NAC was associated with lower response rates in plasma, urine supernatant, and urine pellet (P < 0.001, P = 0.03, P = 0.002). Tumor DNA dynamics during NAC was predictive of NAC response and outcome in urine supernatant and plasma (P = 0.006 and P = 0.002). A combined measure from plasma and urine supernatant tumor DNA dynamics stratified patients by outcome (P = 0.003).Conclusions:Analysis of tumor DNA in plasma and urine samples both separately and combined has a potential to predict treatment response and outcome.
- Open Access
- 14 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S13 from Cell-Free Urine and Plasma DNA Mutational Analysis Predicts Neoadjuvant Chemotherapy Response and Outcome in Patients with Muscle-Invasive Bladder Cancer
Supplementary Fig. 1. Overview of sample availability and in-silico analysis of the limit of detection for the applied methodology.Supplementary Fig. 2. Comparison between mutations observed in primary and residual tumors at radical cystectomy (RC).Supplementary Fig. 3. Mean sample VAF levels for plasma, urine pellet and urine supernatant split by tdDNA call status in other paired sample types from the same clinical visit.Supplementary Fig. 4. Association between mean sample VAF.Supplementary Fig. 5. Association between mean VAFSupplementary Fig. 6. Urine dipstick measurements compared to the amount of DNA extracted from urine supernatants collected at the same time (+/- 1 day).Supplementary Fig. 7. Urine dipstick measurements compared to the urinary tumor DNA (utDNA) call status in urine supernatants collected at the same time (+/- 1 day).Supplementary Fig. 8. Urine dipstick measurements compared to the urinary tumor DNA (utDNA) level in urine supernatants collected at the same time (+/- 1 day).Supplementary Fig. 9. Mean sample VAF levels for all patients with detectable tumor DNA split by sample type. Tumor stage evaluation was based on the TURB specimen and tumor DNA level based on samples collected before TURB.Supplementary Fig. 10. Kaplan-Meier survival analysis of recurrence-free survival (RFS) stratified by tumor DNA status for all sample types.Supplementary Fig. 11. Tumor DNA levels compared to NAC response.Supplementary Fig. 12. Kaplan-Meier survival analysis of recurrence-free survival (RFS) stratified by tumor DNA level for all sample types.Supplementary Fig. 13. a-b) Association between tumor DNA dynamics and neoadjuvant chemotherapy (NAC) response for a) urine pellet and b) urine supernatant. Tumor DNA clearance was defined as tumor DNA going from detectable to non-detectable and tumor DNA remains was defined as tumor DNA remaining detectable. c-d) Kaplan-Meier survival analysis of tumor DNA dynamics groups and recurrence-free survival (RFS) for c) urine pellet and d) urine supernatant.
- 14 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S13 from Cell-Free Urine and Plasma DNA Mutational Analysis Predicts Neoadjuvant Chemotherapy Response and Outcome in Patients with Muscle-Invasive Bladder Cancer
Supplementary Fig. 1. Overview of sample availability and in-silico analysis of the limit of detection for the applied methodology.Supplementary Fig. 2. Comparison between mutations observed in primary and residual tumors at radical cystectomy (RC).Supplementary Fig. 3. Mean sample VAF levels for plasma, urine pellet and urine supernatant split by tdDNA call status in other paired sample types from the same clinical visit.Supplementary Fig. 4. Association between mean sample VAF.Supplementary Fig. 5. Association between mean VAFSupplementary Fig. 6. Urine dipstick measurements compared to the amount of DNA extracted from urine supernatants collected at the same time (+/- 1 day).Supplementary Fig. 7. Urine dipstick measurements compared to the urinary tumor DNA (utDNA) call status in urine supernatants collected at the same time (+/- 1 day).Supplementary Fig. 8. Urine dipstick measurements compared to the urinary tumor DNA (utDNA) level in urine supernatants collected at the same time (+/- 1 day).Supplementary Fig. 9. Mean sample VAF levels for all patients with detectable tumor DNA split by sample type. Tumor stage evaluation was based on the TURB specimen and tumor DNA level based on samples collected before TURB.Supplementary Fig. 10. Kaplan-Meier survival analysis of recurrence-free survival (RFS) stratified by tumor DNA status for all sample types.Supplementary Fig. 11. Tumor DNA levels compared to NAC response.Supplementary Fig. 12. Kaplan-Meier survival analysis of recurrence-free survival (RFS) stratified by tumor DNA level for all sample types.Supplementary Fig. 13. a-b) Association between tumor DNA dynamics and neoadjuvant chemotherapy (NAC) response for a) urine pellet and b) urine supernatant. Tumor DNA clearance was defined as tumor DNA going from detectable to non-detectable and tumor DNA remains was defined as tumor DNA remaining detectable. c-d) Kaplan-Meier survival analysis of tumor DNA dynamics groups and recurrence-free survival (RFS) for c) urine pellet and d) urine supernatant.
- Open Access
- 14 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Cell-Free Urine and Plasma DNA Mutational Analysis Predicts Neoadjuvant Chemotherapy Response and Outcome in Patients with Muscle-Invasive Bladder Cancer
Summarized metrics for WES data
- 14 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Cell-Free Urine and Plasma DNA Mutational Analysis Predicts Neoadjuvant Chemotherapy Response and Outcome in Patients with Muscle-Invasive Bladder Cancer
Summarized metrics for WES data
- Open Access
- 14 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S13 from Cell-Free Urine and Plasma DNA Mutational Analysis Predicts Neoadjuvant Chemotherapy Response and Outcome in Patients with Muscle-Invasive Bladder Cancer
Supplementary Fig. 1. Overview of sample availability and in-silico analysis of the limit of detection for the applied methodology.Supplementary Fig. 2. Comparison between mutations observed in primary and residual tumors at radical cystectomy (RC).Supplementary Fig. 3. Mean sample VAF levels for plasma, urine pellet and urine supernatant split by tdDNA call status in other paired sample types from the same clinical visit.Supplementary Fig. 4. Association between mean sample VAF.Supplementary Fig. 5. Association between mean VAFSupplementary Fig. 6. Urine dipstick measurements compared to the amount of DNA extracted from urine supernatants collected at the same time (+/- 1 day).Supplementary Fig. 7. Urine dipstick measurements compared to the urinary tumor DNA (utDNA) call status in urine supernatants collected at the same time (+/- 1 day).Supplementary Fig. 8. Urine dipstick measurements compared to the urinary tumor DNA (utDNA) level in urine supernatants collected at the same time (+/- 1 day).Supplementary Fig. 9. Mean sample VAF levels for all patients with detectable tumor DNA split by sample type. Tumor stage evaluation was based on the TURB specimen and tumor DNA level based on samples collected before TURB.Supplementary Fig. 10. Kaplan-Meier survival analysis of recurrence-free survival (RFS) stratified by tumor DNA status for all sample types.Supplementary Fig. 11. Tumor DNA levels compared to NAC response.Supplementary Fig. 12. Kaplan-Meier survival analysis of recurrence-free survival (RFS) stratified by tumor DNA level for all sample types.Supplementary Fig. 13. a-b) Association between tumor DNA dynamics and neoadjuvant chemotherapy (NAC) response for a) urine pellet and b) urine supernatant. Tumor DNA clearance was defined as tumor DNA going from detectable to non-detectable and tumor DNA remains was defined as tumor DNA remaining detectable. c-d) Kaplan-Meier survival analysis of tumor DNA dynamics groups and recurrence-free survival (RFS) for c) urine pellet and d) urine supernatant.
- 14 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S13 from Cell-Free Urine and Plasma DNA Mutational Analysis Predicts Neoadjuvant Chemotherapy Response and Outcome in Patients with Muscle-Invasive Bladder Cancer
Supplementary Fig. 1. Overview of sample availability and in-silico analysis of the limit of detection for the applied methodology.Supplementary Fig. 2. Comparison between mutations observed in primary and residual tumors at radical cystectomy (RC).Supplementary Fig. 3. Mean sample VAF levels for plasma, urine pellet and urine supernatant split by tdDNA call status in other paired sample types from the same clinical visit.Supplementary Fig. 4. Association between mean sample VAF.Supplementary Fig. 5. Association between mean VAFSupplementary Fig. 6. Urine dipstick measurements compared to the amount of DNA extracted from urine supernatants collected at the same time (+/- 1 day).Supplementary Fig. 7. Urine dipstick measurements compared to the urinary tumor DNA (utDNA) call status in urine supernatants collected at the same time (+/- 1 day).Supplementary Fig. 8. Urine dipstick measurements compared to the urinary tumor DNA (utDNA) level in urine supernatants collected at the same time (+/- 1 day).Supplementary Fig. 9. Mean sample VAF levels for all patients with detectable tumor DNA split by sample type. Tumor stage evaluation was based on the TURB specimen and tumor DNA level based on samples collected before TURB.Supplementary Fig. 10. Kaplan-Meier survival analysis of recurrence-free survival (RFS) stratified by tumor DNA status for all sample types.Supplementary Fig. 11. Tumor DNA levels compared to NAC response.Supplementary Fig. 12. Kaplan-Meier survival analysis of recurrence-free survival (RFS) stratified by tumor DNA level for all sample types.Supplementary Fig. 13. a-b) Association between tumor DNA dynamics and neoadjuvant chemotherapy (NAC) response for a) urine pellet and b) urine supernatant. Tumor DNA clearance was defined as tumor DNA going from detectable to non-detectable and tumor DNA remains was defined as tumor DNA remaining detectable. c-d) Kaplan-Meier survival analysis of tumor DNA dynamics groups and recurrence-free survival (RFS) for c) urine pellet and d) urine supernatant.
- Open Access
- 14 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Cell-Free Urine and Plasma DNA Mutational Analysis Predicts Neoadjuvant Chemotherapy Response and Outcome in Patients with Muscle-Invasive Bladder Cancer
Clinical data and follow-up data
- 14 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Cell-Free Urine and Plasma DNA Mutational Analysis Predicts Neoadjuvant Chemotherapy Response and Outcome in Patients with Muscle-Invasive Bladder Cancer
Clinical data and follow-up data
- Open Access
- 14 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Cell-Free Urine and Plasma DNA Mutational Analysis Predicts Neoadjuvant Chemotherapy Response and Outcome in Patients with Muscle-Invasive Bladder Cancer
Summarized metrics for WES data
- 14 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Cell-Free Urine and Plasma DNA Mutational Analysis Predicts Neoadjuvant Chemotherapy Response and Outcome in Patients with Muscle-Invasive Bladder Cancer
Summarized metrics for WES data